Download PDF
Open Access
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1811967
Original Article

Role of Pretreatment Pan-Immune Inflammation Value as Predictive Marker of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Prospective Observational Study in a Tertiary Cancer Center

Authors

  • KN Lokesh 

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • Patidar Yaman 

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • R.S. Darshan 

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • Rudresh AH

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • L.K. Rajeev

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • Smitha C. Saldanha

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

  • G.V. Giri

    2   Department of Medicine, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India

  • Suresh Babu MC

    1   Department of Medical Oncology, Kidwai Memorial Institute of Oncology (KMIO), Bengaluru, Karnataka, India

Funding None.
Further Information
Also available at
  Permissions and Reprints
Preview

Abstract

Introduction

Neoadjuvant treatment in locally advanced rectal cancer (LARC) led to downstaging in nearly 50 to 60% of patients and pathological complete response (pCR) rates in 9 to 30% cases. However, cases not responding to neoadjuvant treatment encounter either a delay in definitive treatment or progression.

Objective

To evaluate the role of pan-immune inflammation value (PIV) as a predictive marker of response to neoadjuvant therapy in LARC.

Materials and Methods

A prospective observational study was conducted to validate the predictive value of response to pretreatment PIV in patients with LARC.

Results

One hundred twenty patients were enrolled in the study. Patients with higher PIV values were found to have poorer radiological response as compared with patients with lower values (55.1 vs. 75.8%, p = 0.045). Also, patients with high micro-satellite instability status had poor responses. pCR was seen in 21 patients (19.6%). Patients with high PIV value had a pCR rate of 11.6% as compared with 34.0% in the low PIV group.

Conclusion

Pretreatment PIV value appears to be a predictive marker of response to neoadjuvant treatment in LARC.

Keywords

pan-immune inflammation value - rectal neoplasm - pathologic complete response - neoadjuvant therapy

Patient's Consent

Informed consent was taken from each patient.


The manuscript has been read and approved by above mentioned authors and each author believes that the manuscript represents honest work.




Publication History

Article published online:
25 September 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India